Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 20/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vociprotafib SCHEMBL29449814 | 1.00 | PTPN11 (1.00) | PTPN11EGFRKCNH2MAPK3MAPK1 | |
| SCHEMBL21154584 | 0.93 | PTPN11 (0.86) | PTPN11EGFRKCNH2 | |
| SCHEMBL22694112 | 0.92 | PTPN11 (0.85) | PTPN11EGFRKCNH2MAPK3MAPK1 | |
| SCHEMBL30296101 | 0.91 | PTPN11 (0.84) | PTPN11EGFRKCNH2 | |
| SCHEMBL19785524 | 0.91 | PTPN11 (0.84) | PTPN11EGFRKCNH2 | |
| SCHEMBL30759506 | 0.91 | PTPN11 (0.83) | PTPN11EGFRKCNH2MAPK3MAPK1 | |
| SCHEMBL24233645 | 0.90 | PTPN11 (0.82) | PTPN11EGFRKCNH2MAPK3MAPK1 | |
| SCHEMBL19785359 | 0.90 | PTPN11 (0.81) | PTPN11EGFRKCNH2 | |
| SCHEMBL19785589 | 0.90 | PTPN11 (0.81) | PTPN11EGFRKCNH2 | |
| SCHEMBL30295728 | 0.90 | PTPN11 (0.81) | PTPN11EGFRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144793-A1 | METHODS OF TREATING CANCER | AMGEN INC. (US) | 2026-05-28 | — | — | US | claimed |
| US-12528807-B2 | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl} methanol, a SHP2 inhibitor | Revolution Medicines, Inc. (US) | 2026-01-20 | — | — | US | claimed |
| WO-2024015360-A1 | METHODS OF TREATING CANCER | AMGEN INC. (US) | 2024-01-18 | — | — | WO | claimed |
| US-20220298159-A1 | SOLID FORMS OF {6-[(2-AMINO-3-CHLOROPYRIDIN-4-YL)SULFANYL]-3-[(3S,4S)-4-AMINO-3-METHYL-2-OXA-8-AZASPIRO[4.5]DECAN-8-YL]-5-METHYLPYRAZIN-2-YL}METHANOL, A SHP2 INHIBITOR | Revolution Medicines, Inc. (US) | 2022-09-22 | — | — | US | claimed |
| EP-3980128-A1 | SOLID FORMS OF {6-[(2-AMINO-3-CHLOROPYRIDIN-4-YL)SULFANYL]-3-[(3S,4S)-4-AMINO-3-METHYL-2-OXA-8-AZASPIRO[4.5]DECAN-8-YL]-5-METHYLPYRAZIN-2-YL}METHANOL, AN SHP2 INHIBITOR | Revolution Medicines, Inc. (US) | 2022-04-13 | — | — | EP | claimed |
| US-11220501-B2 | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl} methanol, a SHP2 inhibitor | Revolution Medicines, Inc. (US) | 2022-01-11 | — | — | US | claimed |
| US-20210253574-A1 | SOLID FORMS OF {6-[(2-AMINO-3-CHLOROPYRIDIN-4-YL)SULFANYL]-3-[(3S,4S)-4-AMINO-3-METHYL-2-OXA-8-AZASPIRO[4.5]DECAN-8-YL]-5-METHYLPYRAZIN-2-YL}METHANOL, AN SHP2 INHIBITOR | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-08-19 | — | — | US | claimed |
| WO-2020247643-A1 | SOLID FORMS OF {6-[(2-AMINO-3-CHLOROPYRIDIN-4-YL)SULFANYL]-3-[(3S,4S)-4-AMINO-3-METHYL-2-OXA-8-AZASPIRO[4.5]DECAN-8-YL]-5-METHYLPYRAZIN-2-YL}METHANOL, AN SHP2 INHIBITOR | Revolution Medicines, Inc. (US) | 2020-12-10 | — | — | WO | claimed |
| US-20260144793-A1 | METHODS OF TREATING CANCER | AMGEN INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12565476-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| US-12528807-B2 | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl} methanol, a SHP2 inhibitor | Revolution Medicines, Inc. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12528807-B2 | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl} methanol, a SHP2 inhibitor | Revolution Medicines, Inc. (US) | 2026-01-20 | — | — | US | disclosed |
| WO-2024015360-A1 | METHODS OF TREATING CANCER | AMGEN INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| EP-4302834-A2 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| US-20210101870-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-04-08 | — | — | US | disclosed |
| WO-2020247643-A1 | SOLID FORMS OF {6-[(2-AMINO-3-CHLOROPYRIDIN-4-YL)SULFANYL]-3-[(3S,4S)-4-AMINO-3-METHYL-2-OXA-8-AZASPIRO[4.5]DECAN-8-YL]-5-METHYLPYRAZIN-2-YL}METHANOL, AN SHP2 INHIBITOR | Revolution Medicines, Inc. (US) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020247643-A1 | SOLID FORMS OF {6-[(2-AMINO-3-CHLOROPYRIDIN-4-YL)SULFANYL]-3-[(3S,4S)-4-AMINO-3-METHYL-2-OXA-8-AZASPIRO[4.5]DECAN-8-YL]-5-METHYLPYRAZIN-2-YL}METHANOL, AN SHP2 INHIBITOR | Revolution Medicines, Inc. (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20200368238-A1 | SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2020-11-26 | — | — | US | disclosed |
| US-20190210977-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2019-07-11 | — | — | US | disclosed |
| WO-2018013597-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210977-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN2, PTPN22 | PTPN11 12/4885EGFR 980/4885KCNH2 3436/4885 |
| US-12528807-B2 | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl} methanol, a SHP2 inhibitor | PTPN2, PTPN5, PTPN18 | PTPN11 13/4885EGFR 676/4885KCNH2 3299/4885 |
| US-20210101870-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN22, PTPN2 | PTPN11 8/4885EGFR 2069/4885KCNH2 2485/4885 |
| US-20260144793-A1 | METHODS OF TREATING CANCER | KRAS, PTPN11, NRAS | PTPN11 2/4885EGFR 312/4885KCNH2 4087/4885 |
| US-12565476-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN6, PTPN2 | PTPN11 6/4885EGFR 361/4885KCNH2 1681/4885 |
| US-20200368238-A1 | SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | DUSP3, PTPRCAP, PTPN1 | PTPN11 32/4885EGFR 499/4885KCNH2 4786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.